The company will carry out a reverse stock split in a ratio of 1:100. The share will be traded under new ISIN code with effect from May 20, 2026. The order book will not change.
| Short name: | VIVE |
| Terms: | Reverse split: 1:100 |
| Current ISIN: | SE0000722365 |
| Last day of trading with current ISIN code: | May 19, 2026 |
| New ISIN code: | SE0028925701 |
| First day of trading with new ISIN code: | May 20, 2026 |
Nasdaq Stockholm AB, Issuer Surveillance, dl-ilasto@nasdaq.com, +46 8 405 7280
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12:01 | Split and Change of ISIN for Vivesto AB | The company will carry out a reverse stock split in a ratio of 1:100. The share will be traded under new ISIN code with effect from May 20, 2026. The order book will not change.
... ► Artikel lesen | |
| Mi | Vivesto AB: Vivesto announces timetable for reverse share split | At the Annual General Meeting in Vivesto AB ("Vivesto" or the "Company") on 7 May 2026, it was resolved to carry out a reverse share split of 1:100, entailing that one hundred (100) shares are consolidated... ► Artikel lesen | |
| 07.05. | Vivesto AB: Report from Annual General Meeting in Vivesto AB | At the Annual General Meeting in Vivesto AB ("Vivesto" or the "company") held on 7 May 2026, the following resolutions were passed. All resolutions were in accordance with the proposals, described in... ► Artikel lesen | |
| 01.04. | Vivesto AB: The Board of Directors of Vivesto proposes a reverse share split and reduction of the share capital | The Board of Directors of Vivesto AB ("Vivesto" or the "Company") has resolved to propose that the Annual General Meeting on 7 May 2026 resolves on a reverse share split, whereby one hundred (100) existing... ► Artikel lesen | |
| 13.03. | Vivesto AB: First dogs dosed in Vivesto's PK/toxicology study with Cantrixil | Solna, Sweden, March 13, 2026 - Vivesto AB, an oncology-focused development company, today announces that the first dogs have been dosed in the company's ongoing pharmacokinetic (PK) and toxicology... ► Artikel lesen |
